研究者業績

白井 克幸

Katsuyuki SHIRAI

基本情報

所属
自治医科大学 附属病院放射線治療科 教授

J-GLOBAL ID
201601003376230891
researchmap会員ID
7000016344

論文

 118
  • Katsuyuki Shirai, Shuri Aoki, Masashi Endo, Yuta Takahashi, Yukiko Fukuda, Keiko Akahane, Atsushi Musha, Harutoshi Sato, Masaru Wakatsuki, Hitoshi Ishikawa, Ryohei Sasaki
    Japanese journal of radiology 2024年9月24日  
    Lung cancer has a poor prognosis, and further improvements in outcomes are needed. Radiotherapy plays an important role in the treatment of unresectable lung cancer, and there have been recent developments in the field of radiotherapy for the management of lung cancer. However, to date, there have been few reviews on the improvement in treatment outcomes associated with high precision radiotherapy for lung cancer. Thus, this review aimed to summarize the recent developments in radiotherapy techniques and indicate the future directions in the use of radiotherapy for lung cancer. Stereotactic body radiotherapy (SBRT) for unresectable stage I lung cancer has been reported to improve local control rates without severe adverse events, such as radiation pneumonitis. For locally advanced lung cancer, a combination of chemoradiotherapy and adjuvant immune checkpoint inhibitors dramatically improves treatment outcomes, and intensity-modulated radiotherapy (IMRT) enables safer radiation therapy with less frequent pneumonitis. Particle beam therapy, such as carbon-ion radiotherapy and proton beam therapy, has been administered as advanced medical care for patients with lung cancer. Since 2024, it has been covered under insurance for early stage lung cancer with tumors ≤ 5 cm in size in Japan. In addition to chemotherapy, local ablative radiotherapy improves treatment outcomes in patients with oligometastatic stage IV lung cancer. A particular problem with radiotherapy for lung cancer is that the target location changes with respiratory motion, and various physical methods have been used to control respiratory motion. Recently, coronavirus disease has had a major impact on lung cancer treatment, and cancer treatment during situations, such as the coronavirus pandemic, must be performed carefully. To improve treatment outcomes for lung cancer, it is necessary to fully utilize evolving radiotherapy modalities, and the role of radiotherapy in lung cancer treatment is expected to increase.
  • Masahiro Kawahara, Akira Tanaka, Keiko Akahane, Masashi Endo, Yukiko Fukuda, Kohei Okada, Kazunari Ogawa, Satoru Takahashi, Michiko Nakamura, Tsuzumi Konishi, Kimitoshi Saito, Satoshi Washino, Tomoaki Miyagawa, Masahiro Hiruta, Hisashi Oshiro, Noriko Oyama-Manabe, Katsuyuki Shirai
    Cancer diagnosis & prognosis 4(6) 715-721 2024年  
    BACKGROUND/AIM: In prostate cancer, robotic total prostatectomy is a popular treatment modality. However, prostate-specific antigen (PSA) recurrence after prostate cancer surgery remains a concern. Salvage radiotherapy is commonly used to treat PSA recurrence, but the recurrence rate after salvage radiotherapy is high, highlighting the need for better predictive markers. This study aimed to retrospectively evaluate the association between cribriform pattern and PSA recurrence in patients receiving radiotherapy after radical prostatectomy. PATIENTS AND METHODS: Data of 50 patients who underwent radiotherapy after total prostatectomy between January 2010 and May 2020 were retrospectively evaluated. The median age was 67 years. Among these patients, two cases involved postoperative irradiation, while 48 cases involved salvage irradiation after postoperative PSA recurrence. The median time from surgery to PSA recurrence was 38.3 months. The median radiation dose was 64 Gy in 32 fractions. Three-dimensional conformal radiation therapy was administered in 38 cases and intensity-modulated radiation therapy was used in 12 cases. Combined hormone therapy was administered in 21 cases. PSA levels were measured every 3 months after treatment. Statistical analysis between groups was performed by a t-test. RESULTS: The median follow-up period after radiotherapy was 31 months. No local recurrences were observed at the prostate bed, and no deaths related to prostate cancer were recorded during follow-up. However, 18 patients (36.0%) had PSA recurrence. The PSA recurrence rate based on the cribriform pattern was 17.6% in the none to moderate group (34 patients) and 75.0% in the severe cribriform pattern group (16 patients). The PSA recurrence rate was significantly higher in patients with a severe invasive cribriform pattern (p=0.001). No significant differences were observed in other histopathological characteristics. CONCLUSION: The cribriform pattern in surgical pathology specimens was found to be a useful predictor of PSA recurrence after postoperative radiotherapy.
  • Osamu Manabe, Hiroyuki Jinnouchi, Tadao Aikawa, Katsuyuki Shirai, Noriko Oyama-Manabe
    European heart journal. Cardiovascular Imaging 2023年9月28日  
  • Masashi Endo, Yukiko Fukuda, Kohei Okada, Kazunari Ogawa, Michiko Nakamura, Satoru Takahashi, Eri Murakami, Chiaki Shibayama, Masahiro Kawahara, Keiko Akahane, Ryutaro Onaga, Takafumi Nagatomo, Takeharu Kanazawa, Hiroshi Nishino, Harushi Mori, Katsuyuki Shirai
    In Vivo 37(5) 2320-2326 2023年9月  
    Background/Aim: Accelerated hyperfractionation (AHF) is used in head and neck cancer to improve the local control (LC) rate, but reports of outcomes for early-stage GC are limited. The outcomes of radiotherapy (RT) for stage 1 glottic carcinoma (GC) were retrospectively analyzed, comparing AHF and once-daily fractionation (ODF) using 2.0-2.4 Gy. Patients and Methods: A total of 102 patients with stage 1 GC underwent RT alone between 2007 and 2021, with 43 in the AHF group and 59 in the ODF group. A p-value less than 0.05 was considered to indicate a significant difference. Results: The 5-year LC rate was 98% in the AHF group and 91% in the ODF group (p=0.19). During RT, significantly more patients in the AHF group required opioids due to mucositis than in the ODF group (74% vs. 25%, p<0.001), and the rate of aspiration pneumonia tended to be higher in the AHF group than in the ODF group (7% vs. 0%, p=0.072). Conclusion: There was no difference in the LC rate between AHF and ODF for stage 1 GC. Moreover, the AHF group required opioids at a higher rate and tended to have a higher risk of developing aspiration pneumonia.
  • MASASHI ENDO, YUKIKO FUKUDA, KOHEI OKADA, KAZUNARI OGAWA, MICHIKO NAKAMURA, SATORU TAKAHASHI, ERI MURAKAMI, CHIAKI SHIBAYAMA, MASAHIRO KAWAHARA, KEIKO AKAHANE, RYUTARO ONAGA, TAKAFUMI NAGATOMO, TAKEHARU KANAZAWA, HIROSHI NISHINO, HARUSHI MORI, KATSUYUKI SHIRAI
    In Vivo 37(5) 2320-2326 2023年8月31日  

MISC

 147

共同研究・競争的資金等の研究課題

 8